# Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS)

> **NCT03377725** · PHASE3 · WITHDRAWN · sponsor: **Li Junmin**

## Conditions studied

- Myelodysplastic Syndromes
- P53 Mutation

## Interventions

- **DRUG:** Decitabine
- **DRUG:** Arsenic Trioxide

## Key facts

- **NCT ID:** NCT03377725
- **Lead sponsor:** Li Junmin
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-03-20
- **Primary completion:** 2018-03-31
- **Final completion:** 2018-03-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No patient was involved.
- **Last updated:** 2023-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03377725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03377725, "Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03377725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*